文献速递类风湿关节炎

类风湿关节炎患者使用JAK抑制剂与生物改善病情抗风湿药的主要不良心血管事件发生率比较:来自国际注册协作的数据

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries.
PubMed 文献 · Arthritis Rheumatol · 2025-05-21

基于JAK-pot协作15个注册库中51,233例类风湿关节炎患者的73,008个治疗疗程,比较JAK抑制剂、肿瘤坏死因子抑制剂与其他作用机制生物改善病情抗风湿药的主要不良心血管事件发生率。中位随访1.3年,JAK抑制剂与肿瘤坏死因子抑制剂发生率相似(校正IRR 0.89,95%CI 0.63-1.25),其他作用机制生物改善病情抗风湿药发生率较高(校正IRR 1.35,95%CI 1.10-1.66)。观察性数据显示JAK抑制剂使用前两年未见心血管事件增加。

要点

  • JAK抑制剂与肿瘤坏死因子抑制剂的主要不良心血管事件发生率相似(校正IRR 0.89,95%CI 0.63-1.25)。
  • 其他作用机制生物改善病情抗风湿药发生率高于肿瘤坏死因子抑制剂(校正IRR 1.35,95%CI 1.10-1.66)。
  • 中位随访1.3年,随访主要集中在治疗前两年。

核心结论

  • 观察性数据显示,在一般类风湿关节炎人群中,JAK抑制剂使用前两年与肿瘤坏死因子抑制剂相比未见心血管事件增加的证据。

研究设计与样本

  • 多国真实世界人群研究,纳入JAK-pot协作15个注册库的类风湿关节炎患者。
  • 纳入73,008个治疗疗程(JAK抑制剂16,417个、肿瘤坏死因子抑制剂35,373个、其他作用机制生物改善病情抗风湿药21,218个),共51,233例患者,828例发生主要不良心血管事件。
  • 采用两种分析方法:对主要不良心血管事件超过25例的注册库进行注册库内分析并荟萃国家特定估计,以及个体水平数据合并分析。
  • 使用校正线性混合泊松回归计算治疗组间主要不良心血管事件的发生率比(IRR),并考虑多次治疗疗程。

主要发现

  • 中位随访时间为1.3年,大部分随访集中在治疗前两年。
  • JAK抑制剂、肿瘤坏死因子抑制剂和其他作用机制生物改善病情抗风湿药的发生率分别为每1000人年7.0、7.6和11.8。
  • 与肿瘤坏死因子抑制剂相比,JAK抑制剂的校正IRR为0.89(95%CI 0.63-1.25),其他作用机制生物改善病情抗风湿药的校正IRR为1.35(95%CI 1.10-1.66)。
  • 合并分析显示相似结果。

局限性

  • 中位随访时间1.3年,大部分随访集中在治疗前两年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease-modifying antirheumatic drugs with other modes of action (bDMARD-OMA) in a multicountry, real-world population. METHODS: Patients with RA from 15 registries in the JAK-pot collaboration were included. MACE incidence was analyzed using two approaches: a within-registry analysis aggregating country-specific estimates from registers with >25 incident MACEs through meta-analysis and an individual-level data combined analysis. We used adjusted linear mixed Poisson regression to obtain incidence rate ratios (IRRs) of MACEs between treatment groups, accounting for multiple treatment courses. RESULTS: The study included 73,008 treatment courses (16,417 JAKi, 35,373 TNFi, and 21,218 bDMARD-OMA) and 828 incident MACEs among 51,233 patients. Median follow-up time was 1.3 years, with most of the follow-up concentrated in the first two years of treatment. Incidence rates were 7.0, 7.6, and 11.8 per 1,000 person-years for JAKi, TNFi, and bDMARD-OMA, respectively. Compared to TNFi, JAKi (within-registry adjusted IRR 0.89, 95% confidence interval [CI] 0.63-1.25) had similar incidence rates of MACEs and bDMARD-OMA had higher rates (within-registry adjusted IRR 1.35, 95% CI 1.10-1.66). Combined analysis showed similar results. CONCLUSION: Observational data from the JAK-pot collaboration show no evidence of an increase in cardiovascular events during the first two years of use with JAKi compared to TNFi in the general RA population.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Aymon R, Mongin D, Guemara R, et al. Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. Arthritis Rheumatol. 2025. PMID: 40230232. doi:10.1002/art.43188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。